Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Graham McIlroy

Showing results (11-20 of 37) with videos related to

Pageof 4
Sort By:
Nature Neuroscience|July 30, 2013
Toll-6 and Toll-7 function as neurotrophin receptors in the Drosophila melanogaster CNSGraham McIlroy, Istvan Foldi, Jukka Aurikko, et al.
British Journal of Haematology|June 28, 2017
Increased fracture risk in plasma cell dyscrasias is associated with poorer overall survivalGraham McIlroy, Jemma Mytton, Felicity Evison, et al.
BMC Medical Research Methodology|May 3, 2025
The REFRACT trial: implementation of Bayesian power priors in a randomised, sequential phase II adaptive platform trialCharlotte Gaskell, Kim Linton, Mark Bishton, et al.
Leukemia & Lymphoma|May 14, 2019
Reduced intensity alemtuzumab-containing allogeneic stem cell transplantation for relapsed/refractory low grade lymphoma: reflections on a single center experienceClaire Horgan, Shereef Elmoamly, Graham McIlroy, et al.
Leukemia & Lymphoma|August 13, 2019
Mixed T-cell chimerism at 3 months followed by donor lymphocyte infusion is independently associated with favorable outcomes in alemtuzumab-based reduced-intensity allogeneic hematopoietic stem cell transplantationGraham McIlroy, Emmanouil Nikolousis, Nervana Abou-Zeid, et al.
Cell Reports. Medicine|September 8, 2022
Vaccine subtype and dose interval determine immunogenicity of primary series COVID-19 vaccines in older peopleHelen Parry, Rachel Bruton, Reni Ayodele, et al.
BMC Cancer|January 9, 2025
Fedratinib combined with ropeginterferon alfa-2b in patients with myelofibrosis (FEDORA): study protocol for a multicentre, open-label, Bayesian phase II trialGraham McIlroy, Charlotte Gaskell, Aimee Jackson, et al.
Blood Cancer Journal|March 16, 2023
Delayed diagnosis resulting in increased disease burden in multiple myeloma: the legacy of the COVID-19 pandemicJonathan Carmichael, Frances Seymour, Graham McIlroy, et al.
Bone Marrow Transplantation|August 27, 2021
Azacitidine for the treatment of steroid-refractory chronic graft-versus-host disease: the results of the phase II AZTEC clinical trialRam Malladi, Ikhlaaq Ahmed, Graham McIlroy, et al.
British Journal of Haematology|January 22, 2024
The management of newly diagnosed large B-cell lymphoma: A British Society for Haematology GuidelineChristopher P Fox, Sridhar Chaganti, Graham McIlroy, et al.
Pageof 4

Showing results (11-20 of 37) with videos related to

Sort By:
Pageof 4
Nature Neuroscience|July 30, 2013
Toll-6 and Toll-7 function as neurotrophin receptors in the Drosophila melanogaster CNSGraham McIlroy, Istvan Foldi, Jukka Aurikko, et al.
British Journal of Haematology|June 28, 2017
Increased fracture risk in plasma cell dyscrasias is associated with poorer overall survivalGraham McIlroy, Jemma Mytton, Felicity Evison, et al.
BMC Medical Research Methodology|May 3, 2025
The REFRACT trial: implementation of Bayesian power priors in a randomised, sequential phase II adaptive platform trialCharlotte Gaskell, Kim Linton, Mark Bishton, et al.
Leukemia & Lymphoma|May 14, 2019
Reduced intensity alemtuzumab-containing allogeneic stem cell transplantation for relapsed/refractory low grade lymphoma: reflections on a single center experienceClaire Horgan, Shereef Elmoamly, Graham McIlroy, et al.
Leukemia & Lymphoma|August 13, 2019
Mixed T-cell chimerism at 3 months followed by donor lymphocyte infusion is independently associated with favorable outcomes in alemtuzumab-based reduced-intensity allogeneic hematopoietic stem cell transplantationGraham McIlroy, Emmanouil Nikolousis, Nervana Abou-Zeid, et al.
Cell Reports. Medicine|September 8, 2022
Vaccine subtype and dose interval determine immunogenicity of primary series COVID-19 vaccines in older peopleHelen Parry, Rachel Bruton, Reni Ayodele, et al.
BMC Cancer|January 9, 2025
Fedratinib combined with ropeginterferon alfa-2b in patients with myelofibrosis (FEDORA): study protocol for a multicentre, open-label, Bayesian phase II trialGraham McIlroy, Charlotte Gaskell, Aimee Jackson, et al.
Blood Cancer Journal|March 16, 2023
Delayed diagnosis resulting in increased disease burden in multiple myeloma: the legacy of the COVID-19 pandemicJonathan Carmichael, Frances Seymour, Graham McIlroy, et al.
Bone Marrow Transplantation|August 27, 2021
Azacitidine for the treatment of steroid-refractory chronic graft-versus-host disease: the results of the phase II AZTEC clinical trialRam Malladi, Ikhlaaq Ahmed, Graham McIlroy, et al.
British Journal of Haematology|January 22, 2024
The management of newly diagnosed large B-cell lymphoma: A British Society for Haematology GuidelineChristopher P Fox, Sridhar Chaganti, Graham McIlroy, et al.
Pageof 4